These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 19430284)

  • 1. The article by Kovach and Rosenfeld.
    Charbel Issa P; Holz FG; Scholl HP
    Retina; 2009 May; 29(5):717; author reply 717-8. PubMed ID: 19430284
    [No Abstract]   [Full Text] [Related]  

  • 2. Bevacizumab (avastin) therapy for idiopathic macular telangiectasia type II.
    Kovach JL; Rosenfeld PJ
    Retina; 2009 Jan; 29(1):27-32. PubMed ID: 18936721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Juxtafoveal telangiectasias.
    Querques G; Delle Noci N
    Ophthalmology; 2008 Sep; 115(9):1636; author reply 1636. PubMed ID: 18762079
    [No Abstract]   [Full Text] [Related]  

  • 4. Management of Coats disease with bevacizumab in 2 patients.
    Venkatesh P; Mandal S; Garg S
    Can J Ophthalmol; 2008 Apr; 43(2):245-6. PubMed ID: 18347637
    [No Abstract]   [Full Text] [Related]  

  • 5. Intravitreous ranibizumab as treatment for macular telangiectasia type 2.
    Lira RP; Silva VB; Cavalcanti TM; de Souza AC; Pinto AP
    Arch Ophthalmol; 2010 Aug; 128(8):1075-8. PubMed ID: 20697014
    [No Abstract]   [Full Text] [Related]  

  • 6. Bevacizumab and retinal ischemia.
    Neubauer AS; Kook D; Haritoglou C; Priglinger SG; Kampik A; Ulbig MW; Ceklic L
    Ophthalmology; 2007 Nov; 114(11):2096. PubMed ID: 17980746
    [No Abstract]   [Full Text] [Related]  

  • 7. Combined photodynamic therapy and intravitreal bevacizumab as primary treatment for subretinal neovascularization associated with type 2 idiopathic macular telangiectasia.
    Rishi P; Rishi E; Shroff D
    Indian J Ophthalmol; 2009; 57(3):241-2. PubMed ID: 19384026
    [No Abstract]   [Full Text] [Related]  

  • 8. Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia.
    Charbel Issa P; Holz FG; Scholl HP
    Ophthalmology; 2007 Sep; 114(9):1736-42. PubMed ID: 17822979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia.
    Charbel Issa P; Finger RP; Holz FG; Scholl HP
    Br J Ophthalmol; 2008 Jul; 92(7):941-5. PubMed ID: 18577646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal bevacizumab therapy for idiopathic macular telangiectasia.
    Matsumoto Y; Yuzawa M
    Jpn J Ophthalmol; 2010 Jul; 54(4):320-4. PubMed ID: 20700800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal bevacizumab compared with photodynamic therapy with verteporfin for group 2a parafoveal retinal telangiectasis.
    Windisch R; Kozousek V
    Can J Ophthalmol; 2008 Aug; 43(4):489-90. PubMed ID: 18711474
    [No Abstract]   [Full Text] [Related]  

  • 12. Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation.
    Meyerle CB; Freund KB; Iturralde D; Spaide RF; Sorenson JA; Slakter JS; Klancnik JM; Fisher YL; Cooney MJ; Yannuzzi LA
    Retina; 2007; 27(4):451-7. PubMed ID: 17420697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab in the treatment of idiopathic macular telangiectasia.
    Gamulescu MA; Walter A; Sachs H; Helbig H
    Graefes Arch Clin Exp Ophthalmol; 2008 Aug; 246(8):1189-93. PubMed ID: 18386039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal pegaptanib reduces fluorescein leakage in idiopathic parafoveal telangiectasis.
    Vianna RN; Squeri G; Turquetti R; Brasil OF; Burnier MN
    Can J Ophthalmol; 2008 Aug; 43(4):492-3. PubMed ID: 18711476
    [No Abstract]   [Full Text] [Related]  

  • 15. Ranibizumab for retinal angiomatous proliferation.
    Rouvas AA; Papakostas TD; Ladas ID
    Graefes Arch Clin Exp Ophthalmol; 2009 Dec; 247(12):1719-20. PubMed ID: 19669654
    [No Abstract]   [Full Text] [Related]  

  • 16. Intravitreal bevacizumab (Avastin) in idiopathic retinitis, vasculitis, aneurysms and neuroretinitis.
    Akesbi J; Brousseaud FX; Adam R; Rodallec T; Nordmann JP
    Acta Ophthalmol; 2010 Mar; 88(2):e40-1. PubMed ID: 19508455
    [No Abstract]   [Full Text] [Related]  

  • 17. The effect of intravitreal bevacizumab in the treatment of Coats disease in children.
    Lin CJ; Hwang JF; Chen YT; Chen SN
    Retina; 2010 Apr; 30(4):617-22. PubMed ID: 19996822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comment of article by Matsumoto Y.
    Campa C; D'Angelo S; Incorvaia C
    Retina; 2008 May; 28(5):782; author reply 782-3. PubMed ID: 18463528
    [No Abstract]   [Full Text] [Related]  

  • 19. Intravitreal bevacizumab for peripapillary classic subretinal neovascularization.
    Spandau UH; Jonas JB
    Acta Ophthalmol Scand; 2007 May; 85(3):340-1. PubMed ID: 17488467
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparing ranibizumab with bevacizumab.
    Biswas P; Sengupta S; Choudhary R; Home S; Paul A; Sinha S
    Ophthalmology; 2011 Mar; 118(3):600-600.e2. PubMed ID: 21376243
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.